Modulating Bile Acid Metabolism: The Role of Blautia coccoides in Acute Pancreatitis

Acute pancreatitis (AP) remains a common gastrointestinal emergency, characterized by a rapid progression from pancreatic acinar injury to systemic inflammatory response syndrome. The failure of the intestinal barrier integrity and the subsequent bacterial translocation are associated with infected pancreatic necrosis.¹ Although the descriptive characterization of dysbiosis in AP is well-established, how specific microbes communicate with the host to modulate pancreatic inflammation remains to be further elucidated.² In this issue of Cellular and Molecular Gastroenterology and Hepatology, Fu et al³ provide compelling insights, identifying Blautia coccoides as a probiotic that mediates a protective metabolic cascade via bile salt hydrolase (BSH) activity and farnesoid X receptor (FXR) signaling, thereby effectively alleviating AP.

The authors observed that the abundance of Blautia is significantly reduced in patients with AP and correlates inversely with disease severity. Experiments in vivo demonstrate that gavage with live B. coccoides significantly attenuates pancreatic injury and systemic inflammation. Untargeted metabolomics reveals that B. coccoides reconstitutes secondary bile acid metabolism, which is impaired in AP, among which deoxycholic acid (DCA) exhibited the highest variable importance in projection value. This metabolic feature resonates with our previous cohort study mapping the serum bile acid landscape in patients with AP. Our previous focus was on the regulatory role of primary bile acid metabolism in the liver on pancreatic necrosis.⁴ Here, Fu et al focused on the changes in secondary bile acids mediated by gut microbiota, and demonstrated that DCA is a potent ligand for gut FXR. Activation of intestinal FXR effectively suppresses the NF-κB and NLRP3 inflammatory pathways. This protective role is also confirmed by our recent study, which leverages Mendelian randomization to indicate that predicted higher levels of DCA confer protection against AP, which is validated in multicenter clinical cohorts.⁵ Simultaneously, activation of intestinal FXR triggers the release of fibroblast growth factor 15 (FGF15), an endocrine messenger that is secreted into the portal circulation, subsequently delivered to the pancreas, and binds to FGFR4 on acinar cells, thereby conferring direct protection against injury. This finding aligns with prior research by Phillipp et al, which showed that FXR agonists alleviate alcohol-induced steatohepatitis by stabilizing the gut barrier and regulating FGF15 levels and positions DCA-FXR-FGF15 axis as a potential therapeutic target in AP.⁶ Moreover, DCA also exerts protective effects by modulating the peroxisome proliferator-activated receptor (PPAR) signaling pathway, suggesting that DCA functions through a pleiotropic network involving both nuclear and membrane receptor signaling.⁵

The authors then address an important question: How does B. coccoides augment DCA levels when genomic analysis reveals it lacks the intrinsic bsh genes required for bile acid deconjugation? The innovation of this study lies in its dissection of the mechanism, which distinguishes B. coccoides from traditional probiotics that directly secrete effector molecules. For instance, Lactobacillus secrete Norharman to target histone deacetylases,⁷ Parabacteroides produce acetate to suppress neutrophil infiltration,⁸ and Akkermansia muciniphila utilizes its outer membrane protein Amuc_1409 to stabilize Foxp3 and induce regulatory T cell.⁹ In contrast, B. coccoides acts as a modulator that remodels the gut microecology. It promotes the expansion of BSH-producing genus, specifically Bacteroides and Parabacteroides, likely through cross-feeding mechanisms. This finding is in accordance with the concept of the Foundation Guild recently proposed by Zhao et al, which is a stable, functional coalition that underpins the structural integrity of the microbiome.¹⁰ B. coccoides enriches the guild members that encode bsh, leading to restoration of BSH activity, which catalyzes the deconjugation of primary bile acids. BSH inhibitor and engineered bsh-expressing E. coli are used to further validate this mechanism. This provides convincing evidence that the therapeutic target is the functional restoration of BSH activity rather than the presence of a single taxon.

Clinically, these findings hold certain translational potential. The authors propose a combined microbial signature comprising Blautia, Parabacteroides, and Bacteroides abundance and fecal bsh gene levels, which achieved predictive capability with area under the curve > 90% for distinguishing severe AP from other cases. Furthermore, the study highlights restoration of the BSH–DCA–FXR axis as a viable therapeutic strategy, with approaches such as next-generation probiotics, engineered BSH-expressing bacteria, FXR agonist or FGF15 analogs which are advancing.^11,12 Engineered bacteria are particularly promising because they can be genetically edited to regulate metabolic defects, serve as noninvasive sensors for disease detection, and deliver therapeutic agents to modulate the disease microenvironment.13, 14, 15 Ultimately, these findings shift the focus from single taxa to ecosystem repair, highlighting microbe–microbe interactions that restore functional metabolic production and thereby enhance gut–pancreas crosstalk to enable therapeutic benefit.